ReGenTree reports Phase III data for RGN-259 in dry eye syndrome

In October, ReGenTree LLC reported data from the Phase III ARISE-2 trial in 601 patients with dry eye syndrome showing that RGN-259 (GBT-201) significantly

Read the full 247 word article

User Sign In